Role of Glycogen Synthase Kinase-3 in Interferon-γ-Mediated Immune Hepatitis - PubMed
- ️Sat Jan 01 2022
Review
Role of Glycogen Synthase Kinase-3 in Interferon-γ-Mediated Immune Hepatitis
Chia-Ling Chen et al. Int J Mol Sci. 2022.
Abstract
Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is a vital glycogen synthase regulator controlling glycogen synthesis, glucose metabolism, and insulin signaling. GSK-3 is widely expressed in different types of cells, and its abundant roles in cellular bioregulation have been speculated. Abnormal GSK-3 activation and inactivation may affect its original bioactivity. Moreover, active and inactive GSK-3 can regulate several cytosolic factors and modulate their diverse cellular functional roles. Studies in experimental liver disease models have illustrated the possible pathological role of GSK-3 in facilitating acute hepatic injury. Pharmacologically targeting GSK-3 is therefore suggested as a therapeutic strategy for liver protection. Furthermore, while the signaling transduction of GSK-3 facilitates proinflammatory interferon (IFN)-γ in vitro and in vivo, the blockade of GSK-3 can be protective, as shown by an IFN-γ-induced immune hepatitis model. In this study, we explored the possible regulation of GSK-3 and the potential relevance of GSK-3 blockade in IFN-γ-mediated immune hepatitis.
Keywords: glycogen synthase kinase-3; immune hepatitis; interferon-γ; liver.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

The various roles of GSK-3 contribute to diverse bioactivities and human diseases.

Molecular regulation of GSK-3 for activating the diverse intracellular factors.

The involvement of GSK-3 in IFN-γ signaling.

A hypothetical model for GSK-3-facilitated IFN-γ immune hepatitis. Treatment of ConA causes immune hepatitis through a mechanism involving NKT activation, hepatic cell apoptosis, and inflammatory activation. In activated NKT cells, in addition to CD95L induction, ConA induces GSK-3 activation to facilitate T-bet-modulated IFN-γ generation. Furthermore, signaling of IFN-γ and its receptor IFNGR may cause GSK-3-regulated Jak2/STAT1 signaling in hepatocytes to facilitate IFN-γ-activated Jak2-STAT1 signaling. IFN-γ is essential for inducing hepatic injury, including CD95-mediated hepatic cell death and hepatic inflammatory responses such as iNOS/NO biosynthesis, CD54 induction, and immune T cell and granulocyte infiltration. These findings illustrate a pathogenic role of GSK-3 in guiding ConA-induced immune hepatitis by facilitating IFN-γ expression, signaling, hepatic injury, and inflammation.
Similar articles
-
Kai JI, Huang WC, Tsai CC, Chang WT, Chen CL, Lin CF. Kai JI, et al. J Cell Biochem. 2010 Dec 15;111(6):1522-30. doi: 10.1002/jcb.22881. J Cell Biochem. 2010. PMID: 20872791
-
Noh KT, Son KH, Jung ID, Kang TH, Choi CH, Park YM. Noh KT, et al. J Biol Chem. 2015 May 8;290(19):12394-402. doi: 10.1074/jbc.M114.628578. Epub 2015 Mar 26. J Biol Chem. 2015. PMID: 25814664 Free PMC article.
-
Glycogen synthase kinase-3 facilitates con a-induced IFN-γ-- mediated immune hepatic injury.
Tsai CC, Huang WC, Chen CL, Hsieh CY, Lin YS, Chen SH, Yang KC, Lin CF. Tsai CC, et al. J Immunol. 2011 Oct 1;187(7):3867-77. doi: 10.4049/jimmunol.1100770. Epub 2011 Aug 26. J Immunol. 2011. PMID: 21873526
-
Activator or inhibitor? GSK-3 as a new drug target.
Takahashi-Yanaga F. Takahashi-Yanaga F. Biochem Pharmacol. 2013 Jul 15;86(2):191-9. doi: 10.1016/j.bcp.2013.04.022. Epub 2013 May 2. Biochem Pharmacol. 2013. PMID: 23643839 Review.
-
Association of glycogen synthase kinase-3β with Parkinson's disease (review).
Li DW, Liu ZQ, Chen W, Yao M, Li GR. Li DW, et al. Mol Med Rep. 2014 Jun;9(6):2043-50. doi: 10.3892/mmr.2014.2080. Epub 2014 Mar 28. Mol Med Rep. 2014. PMID: 24681994 Free PMC article. Review.
Cited by
-
Markovska A, Somers K, Guillaume J, Melief J, Mazar AP, Schmitt DM, Schipper HS, Boes M. Markovska A, et al. Sci Rep. 2024 Sep 17;14(1):21710. doi: 10.1038/s41598-024-72492-y. Sci Rep. 2024. PMID: 39289439 Free PMC article.
-
PECAM-1 drives β-catenin-mediated EndMT via internalization in colon cancer with diabetes mellitus.
Wu Q, Du X, Cheng J, Qi X, Liu H, Lv X, Gong X, Shao C, Wang M, Yue L, Yang X, Li S, Zhang Y, Li X, Yang H. Wu Q, et al. Cell Commun Signal. 2023 Aug 14;21(1):203. doi: 10.1186/s12964-023-01193-2. Cell Commun Signal. 2023. PMID: 37580771 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical